DermTech (DMTK) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook
August 8, 2022 4:01 PM EDTLA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its second-quarter 2022 financial results and updated its full-year 2022 outlook.
We continued to set records for many of our key operating and financial metrics in the first half of 2022 despite numerous headwinds, said John Dobak, M.D., CEO, DermTech. Our sales and marketing team continues to be very effective in driving commercial traction, as evidenced by robust billable sample volume and new ordering clinician growth in the second... More
